Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK quad flu vaccine to shake up Germany and UK

This article was originally published in Scrip

Executive Summary

GlaxoSmithKline is poised to take a bigger slice of the influenza prevention market, which, Datamonitor says is worth $3.5 billion in the US, Japan and EU big five. Germany and the UK have approved the quadrivalent flu vaccine under the decentralized procedure and GSK expects to be able to compete in the 2013/13 flu season.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts